Start Date / Time
Friday, Sept. 26, 2025
898 IJK Preston Research Building
| Time | Topic | Speakers |
| 9-9:15 a.m. | Opening Remarks |
|
| 9:15-10:10 a.m. | Former Trainees Remarks |
|
| 10:25-11 a.m. | Clinical Pharmacology and Pharmacogenomics |
|
| 11:15-11:50 a.m. | Ion channel biology |
|
| - Lunch break, box lunches provided - | ||
| 1-2 p.m. | Clinical EP-Heart genetics |
|
| 2:15-3:30 p.m. | Big Data |
|
| 3:45-4:15 p.m. | Closing remarks |
|
+++
Dan M. Roden, MD
Professor of Medicine, Pharmacology, and Biomedical Informatics
Senior Vice-President for Personalized Medicine
Vanderbilt University Medical Center
Dan Roden grew up in Montreal and received his medical degree and trained in Internal Medicine at McGill University. He then came to Vanderbilt where, after fellowships in Clinical Pharmacology and Cardiology, he joined the faculty. His research program studies how genetic variation affects human disease susceptibility, and his special interests are pharmacogenetics, and the genetic determinants of abnormal heart rhythms, especially those induced by drugs. He has been Principal Investigator on NIH awards continuously since 1984. After serving as chief of the division of Clinical Pharmacology for 12 years, he was tasked in 2006 with leading Vanderbilt’s efforts in Personalized Medicine. Under his leadership, Vanderbilt has become internationally recognized for cutting edge programs in this area, including the large (>360,000 samples) biobank BioVU and the EHR-based preemptive pharmacogenetic program PREDICT. He served as Principal Investigator for the Vanderbilt site of the Pharmacogenomics Research Network (2001-2021) and currently serves as co-PI for the Vanderbilt site of the Electronic Medical Records and Genomics (eMERGE) Network, the NHGRI’s genomic Learning Healthcare System network, and the Data and Research Center for the US NIH All of Us program. He has served as primary mentor for 60 MD and/or PhD graduate students and post-doctoral fellows; over half hold appointments in academic departments in the US, Canada, the United Kingdom, France, Germany, Italy, Japan, Australia, and Taiwan; 5 currently serve as deans, department chairs, or division directors.
Dr. Roden has received the Heart Rhythm Society’s Distinguished Scientist Award, the Douglas Zipes lectureship, and the Ralph Lazzara lectureship; the American Society for Clinical Pharmacology and Therapeutics’ Leon Goldberg Young Investigator Award, Rawls Palmer Progress in Science Award, the Oscar Hunter Career Award, and the ASCPT Mentor Award; the Distinguished Scientist Award and the inaugural Functional Genomics and Translational Biology Medal of Honor from the American Heart Association; the Alumnus Lifetime Achievement Award and the Louis and Artur Lucian Award in Cardiovascular Research from McGill; the Jay and Jeanie Schottenstein prize in cardiovascular sciences from the Ohio State University; and Vanderbilt’s Earl Sutherland Award for Achievement in Research. He has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians, and fellowship in the American Association for the Advancement of Science.